Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
- PMID: 15492241
- DOI: 10.1158/0008-5472.CAN-04-1905
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
Abstract
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu-->Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFR(L858R)) and H1666 (EGFR(WT)) are sensitive to gefitinib with IC(50) values of 40 nmol/L and 2 micromol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 micromol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) polymerase cleavage only in the H3255 cell line, leads to G(1)-S arrest in H1666, and has no effects in the A549 and H441 cell lines. Although EGFR and AKT are constitutively phosphorylated in H3255, H1666, and H441 cell lines, AKT is completely inhibited by gefitinib treatment only in the H3255 cell line. These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib.
Similar articles
-
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.Lung Cancer. 2012 Jan;75(1):30-7. doi: 10.1016/j.lungcan.2011.06.001. Epub 2011 Jul 16. Lung Cancer. 2012. PMID: 21757251
-
Targeting apoptosis pathways in lung cancer.Cancer Lett. 2013 May 28;332(2):359-68. doi: 10.1016/j.canlet.2010.09.012. Epub 2010 Oct 25. Cancer Lett. 2013. PMID: 20974517 Review.
-
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.FEBS J. 2010 Jan;277(2):316-26. doi: 10.1111/j.1742-4658.2009.07450.x. Epub 2009 Nov 18. FEBS J. 2010. PMID: 19922467 Review.
-
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760. Clin Cancer Res. 2006. PMID: 17145836
-
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238. J Natl Cancer Inst. 2005. PMID: 16106023
Cited by
-
Modified gefitinib conjugated Fe3O4 NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer.Front Bioeng Biotechnol. 2023 Oct 9;11:1272492. doi: 10.3389/fbioe.2023.1272492. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37877039 Free PMC article.
-
PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC.Cancers (Basel). 2023 Jul 1;15(13):3461. doi: 10.3390/cancers15133461. Cancers (Basel). 2023. PMID: 37444572 Free PMC article.
-
Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system.Nat Commun. 2022 Oct 12;13(1):6004. doi: 10.1038/s41467-022-33788-7. Nat Commun. 2022. PMID: 36224181 Free PMC article.
-
Comprehensive landscape of the ST3GAL family reveals the significance of ST3GAL6-AS1/ST3GAL6 axis on EGFR signaling in lung adenocarcinoma cell invasion.Front Cell Dev Biol. 2022 Aug 26;10:931132. doi: 10.3389/fcell.2022.931132. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36092699 Free PMC article.
-
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.Nat Commun. 2022 May 9;13(1):2530. doi: 10.1038/s41467-022-30258-y. Nat Commun. 2022. PMID: 35534503 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous